Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT

Yoshihiro Inamoto; Igor Petriček; Linda Burns; Saurabh Chhabra; Zack DeFilipp; Peiman Hematti; Alicia Rovó; Raquel Schears; Ami Shah; Vaibhav Agrawal; Aisha Al-Khinji; Ibrahim Ahmed; Asim Ali; Mahmoud Aljurf; Hassan Alkhateeb; Amer Beitinjaneh; Neel Bhatt; Dave Buchbinder; Michael Byrne; Natalie Callander; Kristina Fahnehjelm; Nosha Farhadfar; Robert Peter Gale; Siddhartha Ganguly; Gerhard C. Hildebrandt; Erich Horn; Ann Jakubowski; Rammurti T. Kamble; Jason Law; Catherine Lee; Sunita Nathan; Olaf Penack; Ravi Pingali; Pinki Prasad; Drazen Pulanic; Seth Rotz; Aditya Shreenivas; Amir Steinberg; Khalid Tabbara; André Tichelli; Baldeep Wirk; Jean Yared; Grzegorz W. Basak; Minoo Battiwalla; Rafael Duarte; Bipin N. Savani; Mary E.D. Flowers; Bronwen E. Shaw; Nuria Valdés-Sanz

doi:10.1038/s41409-018-0339-6

Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT

Yoshihiro Inamoto, Igor Petriček, Linda Burns, Saurabh Chhabra, Zack DeFilipp, Peiman Hematti, Alicia Rovó, Raquel Schears, Ami Shah, Vaibhav Agrawal, Aisha Al-Khinji, Ibrahim Ahmed, Asim Ali, Mahmoud Aljurf, Hassan Alkhateeb, Amer Beitinjaneh, Neel Bhatt, Dave Buchbinder, Michael Byrne, Natalie CallanderKristina Fahnehjelm, Nosha Farhadfar, Robert Peter Gale, Siddhartha Ganguly, Gerhard C. Hildebrandt, Erich Horn, Ann Jakubowski, Rammurti T. Kamble, Jason Law, Catherine Lee, Sunita Nathan, Olaf Penack, Ravi Pingali, Pinki Prasad, Drazen Pulanic, Seth Rotz, Aditya Shreenivas, Amir Steinberg, Khalid Tabbara, André Tichelli, Baldeep Wirk, Jean Yared, Grzegorz W. Basak, Minoo Battiwalla, Rafael Duarte, Bipin N. Savani, Mary E.D. Flowers, Bronwen E. Shaw, Nuria Valdés-Sanz

Research output: Contribution to journal › Review article › peer-review

20 Scopus citations

Abstract

Non-graft-vs.-host disease (non-GVHD) ocular complications are generally uncommon after hematopoietic cell transplantation (HCT), but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplant physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment, and ocular toxicities associated with medications. We have summarized incidence, risk factors, screening, prevention and treatment of individual complicastions and generated evidence-based recommendations. Baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up evaluations should be considered according to clinical symptoms, signs and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT. Both transplant physicians and ophthalmologists should be knowledgeable of non-GVHD ocular complications and provide comprehensive collaborative team care.

Original language	English
Pages (from-to)	648-661
Number of pages	14
Journal	Bone Marrow Transplantation
Volume	54
Issue number	5
DOIs	https://doi.org/10.1038/s41409-018-0339-6
State	Published - May 1 2019

Bibliographical note

Publisher Copyright:
© 2019, Springer Nature Limited.

Funding

Acknowledgements The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 4U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-17-1-2388 and N0014-17-1-2850 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, Inc.; *Amgen, Inc.; *Amneal Biosciences; *Angiocrine Bioscience, Inc.; Anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; Atara Biother-apeutics, Inc.; Be the Match Foundation; *bluebird bio, Inc.; *Bristol Myers Squibb Oncology; *Celgene Corporation; Cerus Corporation; *Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Gilead Sciences, Inc.; HistoGenetics, Inc.; Immucor; *Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Juno Therapeutics; Karyopharm Therapeutics, Inc.; Kite Pharma, Inc.; Medac, GmbH; MedImmune; The Medical College of Wisconsin; *Mediware; *Merck & Co, Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; *Neovii Biotech NA, Inc.; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co, Ltd. – Japan; PCORI; *Pfizer, Inc; *Pharmacyclics, LLC; PIRCHE AG; *Sanofi Genzyme; *Seattle Genetics; Shire; Spectrum Pharmaceuticals, Inc.; St. Baldrick’s Foundation; *Sunesis Pharmaceuticals, Inc.; Swedish Orphan Biovitrum, Inc.; Takeda Oncology; Telomere Diagnostics, Inc.; and University of Minnesota. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. *Corporate Members

Funders	Funder number
Actinium Pharmaceuticals, Inc.
AMGEN, Inc.
Amneal Biosciences, *Angiocrine Bioscience
Angiocrine Bioscience, Inc.
HRSA/DHHS	N00014-17-1-2388, N0014-17-1-2850
Office of Naval Research Naval Academy
National Heart, Lung, and Blood Institute Family Blood Pressure Program	U10HL069294
National Heart, Lung, and Blood Institute Family Blood Pressure Program
National Childhood Cancer Registry – National Cancer Institute
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases	HHSH250201200016C
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases
Health Resources and Services Administration
Minnesota State University-Mankato

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1038/s41409-018-0339-6

Fingerprint

Dive into the research topics of 'Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT'. Together they form a unique fingerprint.

Cite this

Inamoto, Y., Petriček, I., Burns, L., Chhabra, S., DeFilipp, Z., Hematti, P., Rovó, A., Schears, R., Shah, A., Agrawal, V., Al-Khinji, A., Ahmed, I., Ali, A., Aljurf, M., Alkhateeb, H., Beitinjaneh, A., Bhatt, N., Buchbinder, D., Byrne, M., ... Valdés-Sanz, N. (2019). Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplantation, 54(5), 648-661. https://doi.org/10.1038/s41409-018-0339-6

@article{5fcd8b9ed79348b594412130e2d909c3,

title = "Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT",

abstract = "Non-graft-vs.-host disease (non-GVHD) ocular complications are generally uncommon after hematopoietic cell transplantation (HCT), but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplant physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment, and ocular toxicities associated with medications. We have summarized incidence, risk factors, screening, prevention and treatment of individual complicastions and generated evidence-based recommendations. Baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up evaluations should be considered according to clinical symptoms, signs and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT. Both transplant physicians and ophthalmologists should be knowledgeable of non-GVHD ocular complications and provide comprehensive collaborative team care.",

author = "Yoshihiro Inamoto and Igor Petri{\v c}ek and Linda Burns and Saurabh Chhabra and Zack DeFilipp and Peiman Hematti and Alicia Rov{\'o} and Raquel Schears and Ami Shah and Vaibhav Agrawal and Aisha Al-Khinji and Ibrahim Ahmed and Asim Ali and Mahmoud Aljurf and Hassan Alkhateeb and Amer Beitinjaneh and Neel Bhatt and Dave Buchbinder and Michael Byrne and Natalie Callander and Kristina Fahnehjelm and Nosha Farhadfar and Gale, \{Robert Peter\} and Siddhartha Ganguly and Hildebrandt, \{Gerhard C.\} and Erich Horn and Ann Jakubowski and Kamble, \{Rammurti T.\} and Jason Law and Catherine Lee and Sunita Nathan and Olaf Penack and Ravi Pingali and Pinki Prasad and Drazen Pulanic and Seth Rotz and Aditya Shreenivas and Amir Steinberg and Khalid Tabbara and Andr{\'e} Tichelli and Baldeep Wirk and Jean Yared and Basak, \{Grzegorz W.\} and Minoo Battiwalla and Rafael Duarte and Savani, \{Bipin N.\} and Flowers, \{Mary E.D.\} and Shaw, \{Bronwen E.\} and Nuria Vald{\'e}s-Sanz",

note = "Publisher Copyright: {\textcopyright} 2019, Springer Nature Limited.",

year = "2019",

month = may,

day = "1",

doi = "10.1038/s41409-018-0339-6",

language = "English",

volume = "54",

pages = "648--661",

number = "5",

}

Inamoto, Y, Petriček, I, Burns, L, Chhabra, S, DeFilipp, Z, Hematti, P, Rovó, A, Schears, R, Shah, A, Agrawal, V, Al-Khinji, A, Ahmed, I, Ali, A, Aljurf, M, Alkhateeb, H, Beitinjaneh, A, Bhatt, N, Buchbinder, D, Byrne, M, Callander, N, Fahnehjelm, K, Farhadfar, N, Gale, RP, Ganguly, S, Hildebrandt, GC, Horn, E, Jakubowski, A, Kamble, RT, Law, J, Lee, C, Nathan, S, Penack, O, Pingali, R, Prasad, P, Pulanic, D, Rotz, S, Shreenivas, A, Steinberg, A, Tabbara, K, Tichelli, A, Wirk, B, Yared, J, Basak, GW, Battiwalla, M, Duarte, R, Savani, BN, Flowers, MED, Shaw, BE & Valdés-Sanz, N 2019, 'Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT', Bone Marrow Transplantation, vol. 54, no. 5, pp. 648-661. https://doi.org/10.1038/s41409-018-0339-6

Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. / Inamoto, Yoshihiro; Petriček, Igor; Burns, Linda et al.
In: Bone Marrow Transplantation, Vol. 54, No. 5, 01.05.2019, p. 648-661.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Non-GVHD ocular complications after hematopoietic cell transplantation

T2 - expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT

AU - Inamoto, Yoshihiro

AU - Petriček, Igor

AU - Burns, Linda

AU - Chhabra, Saurabh

AU - DeFilipp, Zack

AU - Hematti, Peiman

AU - Rovó, Alicia

AU - Schears, Raquel

AU - Shah, Ami

AU - Agrawal, Vaibhav

AU - Al-Khinji, Aisha

AU - Ahmed, Ibrahim

AU - Ali, Asim

AU - Aljurf, Mahmoud

AU - Alkhateeb, Hassan

AU - Beitinjaneh, Amer

AU - Bhatt, Neel

AU - Buchbinder, Dave

AU - Byrne, Michael

AU - Callander, Natalie

AU - Fahnehjelm, Kristina

AU - Farhadfar, Nosha

AU - Gale, Robert Peter

AU - Ganguly, Siddhartha

AU - Hildebrandt, Gerhard C.

AU - Horn, Erich

AU - Jakubowski, Ann

AU - Kamble, Rammurti T.

AU - Law, Jason

AU - Lee, Catherine

AU - Nathan, Sunita

AU - Penack, Olaf

AU - Pingali, Ravi

AU - Prasad, Pinki

AU - Pulanic, Drazen

AU - Rotz, Seth

AU - Shreenivas, Aditya

AU - Steinberg, Amir

AU - Tabbara, Khalid

AU - Tichelli, André

AU - Wirk, Baldeep

AU - Yared, Jean

AU - Basak, Grzegorz W.

AU - Battiwalla, Minoo

AU - Duarte, Rafael

AU - Savani, Bipin N.

AU - Flowers, Mary E.D.

AU - Shaw, Bronwen E.

AU - Valdés-Sanz, Nuria

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Non-graft-vs.-host disease (non-GVHD) ocular complications are generally uncommon after hematopoietic cell transplantation (HCT), but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplant physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment, and ocular toxicities associated with medications. We have summarized incidence, risk factors, screening, prevention and treatment of individual complicastions and generated evidence-based recommendations. Baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up evaluations should be considered according to clinical symptoms, signs and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT. Both transplant physicians and ophthalmologists should be knowledgeable of non-GVHD ocular complications and provide comprehensive collaborative team care.

AB - Non-graft-vs.-host disease (non-GVHD) ocular complications are generally uncommon after hematopoietic cell transplantation (HCT), but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplant physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment, and ocular toxicities associated with medications. We have summarized incidence, risk factors, screening, prevention and treatment of individual complicastions and generated evidence-based recommendations. Baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up evaluations should be considered according to clinical symptoms, signs and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT. Both transplant physicians and ophthalmologists should be knowledgeable of non-GVHD ocular complications and provide comprehensive collaborative team care.

UR - http://www.scopus.com/inward/record.url?scp=85058153231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058153231&partnerID=8YFLogxK

U2 - 10.1038/s41409-018-0339-6

DO - 10.1038/s41409-018-0339-6

M3 - Review article

C2 - 30531955

AN - SCOPUS:85058153231

SN - 0268-3369

VL - 54

SP - 648

EP - 661

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 5

ER -

Inamoto Y, Petriček I, Burns L, Chhabra S, DeFilipp Z, Hematti P et al. Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplantation. 2019 May 1;54(5):648-661. doi: 10.1038/s41409-018-0339-6

Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT

Abstract

Bibliographical note

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this